Mitsubishi UFJ Trust & Banking Corp Acquires 48,208 Shares of Exelixis, Inc. $EXEL

Mitsubishi UFJ Trust & Banking Corp boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 20.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 282,741 shares of the biotechnology company’s stock after acquiring an additional 48,208 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.11% of Exelixis worth $11,677,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Exelixis by 81.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock worth $1,592,000 after purchasing an additional 19,407 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Exelixis by 4.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the period. Focus Partners Wealth boosted its holdings in Exelixis by 83.4% during the first quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock worth $1,420,000 after buying an additional 17,483 shares during the last quarter. Geneos Wealth Management Inc. grew its position in shares of Exelixis by 134.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock worth $61,000 after buying an additional 944 shares during the period. Finally, Sivia Capital Partners LLC increased its stake in shares of Exelixis by 23.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after acquiring an additional 2,764 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Trading Up 0.3%

EXEL stock opened at $43.74 on Wednesday. The stock has a 50-day moving average price of $43.76 and a two-hundred day moving average price of $41.07. Exelixis, Inc. has a 1 year low of $32.30 and a 1 year high of $49.62. The stock has a market cap of $11.73 billion, a PE ratio of 18.46, a price-to-earnings-growth ratio of 0.79 and a beta of 0.40.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.10. Exelixis had a return on equity of 31.06% and a net margin of 29.63%.The company had revenue of $597.76 million for the quarter, compared to analyst estimates of $590.04 million. During the same period in the previous year, the company posted $0.47 earnings per share. The company’s quarterly revenue was up 10.8% compared to the same quarter last year. On average, analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on EXEL shares. Leerink Partners upgraded shares of Exelixis from a “market perform” rating to an “outperform” rating and set a $48.00 price objective for the company in a report on Tuesday, October 21st. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Sunday, December 14th. Royal Bank Of Canada restated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a research report on Tuesday, October 21st. Bank of America downgraded Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective on the stock. in a research note on Monday, January 5th. Finally, Wells Fargo & Company lowered their price target on Exelixis from $36.00 to $30.00 and set an “equal weight” rating for the company in a report on Tuesday, October 21st. Eleven research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $45.95.

Insider Buying and Selling at Exelixis

In other news, Director Mary C. Beckerle sold 24,622 shares of Exelixis stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total value of $1,032,400.46. Following the sale, the director directly owned 21,380 shares in the company, valued at $896,463.40. This trade represents a 53.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stelios Papadopoulos sold 100,000 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $43.55, for a total transaction of $4,355,000.00. Following the transaction, the director owned 1,189,228 shares of the company’s stock, valued at $51,790,879.40. The trade was a 7.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 245,235 shares of company stock valued at $10,490,600 over the last quarter. Insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.